CUSP Merck 057
Posted On: 5/29/2020 10:37 AM
Merck 057- A Phase II Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475)
High risk NMIBC Unresponsive to BCG Therapy.
*Only CIS arm open.
Sponsored by: CUSP
Please contact one of our Clinical Research Coordinators today to find out more information if you are interested in this trial.
Research Department (315) 478-4185, option 3